This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Humedica And Pfizer Form Strategic Alliance

Humedica, Inc. and Pfizer Inc. (NYSE: PFE) today announced a multi-year strategic alliance to jointly advance capabilities to derive insights from real world data.

Humedica, a clinical intelligence company, and Pfizer, the world’s largest research-based biopharmaceutical company, will conduct data-driven collaborative research that will leverage Humedica’s expertise in gathering and normalizing de-identified healthcare data from disparate systems and Pfizer’s experience in researching, developing and commercializing medicines to prevent and treat health conditions. The alliance is an important step in bringing together clinical informatics and life sciences expertise to better understand patient needs and the effectiveness of treatments to improve patient outcomes.

Michael Weintraub, Humedica’s president and CEO, said, “Pfizer's leadership position in global healthcare is focused on the goal of delivery of medicines at optimal effectiveness and efficiency. Humedica is pleased to be Pfizer's clinical informatics and analytics partner, applying Big Data solutions across the continuum of care.”

“The collaboration with Humedica will provide us with powerful information about healthcare delivery and patient outcomes,” said Geno Germano, President and General Manager, Pfizer Specialty Care Business Unit. “By combining leading-edge analytics with unique real world data sets, we believe we can identify actionable insights and potentially improve patient outcomes and overall health.”

About Pfizer

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

About Humedica

Humedica is the foremost clinical intelligence company that provides private cloud based business solutions to the healthcare industry. Humedica’s sophisticated analytics platform transforms disparate clinical data into actionable, real world insights. Powered by the largest and most comprehensive clinical database, Humedica solutions move beyond claims data to offer a more complete, longitudinal view of the patient population. Through its award-winning solutions, Humedica which is headquartered in Boston, empowers its partners and customers to make confident, value-based decisions about patient care in a rapidly changing health care market. For more information, visit http://www.humedica.com. Connect with Humedica on Twitter @humedicainc and Facebook at www.facebook.com/HumedicaInc.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs